Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript

Bausch + Lomb reported Q2 revenue of $1.394B (+8% constant currency) and adjusted EBITDA of $246M (+28% YoY), lifting adjusted EBITDA margin 260 bps to 17.6%. Surgical momentum drove results with premium IOL revenue up 175% (premium mix 13% of Surgical vs 6% in 2025) and implantables up 64% constant currency, while pharmaceuticals grew 14% with Miebo +44% to $91M. The company raised full-year guidance: revenue to $5.440B–$5.540B (+$20M) and adjusted EBITDA to $1.025B–$1.075B (+$15M), alongside stronger cash generation (cash flow from operations $161M; net leverage reduced to ~4.7x, down a full turn). Management also cited an FDA submission for the ELIOS implant-free MIGS excimer laser and expects clinical readouts for dual-action dry eye and ocular surface pain in 2H 2026.

Analysis

The market should treat this less as a simple beat and more as evidence that BLCO is exiting the ‘recovery trade’ and becoming a cash-generative compounder. The important mechanism is mix: premium surgical, branded dry eye, and stronger working capital are pushing EBITDA and free cash flow faster than sales, which is the recipe for multiple expansion even before the pipeline contributes. If that mix holds through 2026, leverage can become a self-reinforcing tailwind rather than an overhang.

The competitive read-through is asymmetric. In surgical optics, BLCO is taking share where surgeon relationships matter most, so the main losers are likely premium IOL incumbents such as ALC rather than commoditized cataract players; in contact lenses, any sustained daily SiHy strength pressures share defenders like COO. The second-order effect is that BLCO’s improving install base should lift consumables and recurring pull-through, making each incremental surgeon win more valuable than the headline revenue suggests.

The risk is that investors may be extrapolating peak momentum into binary R&D outcomes. The enVista Beyond miss is a reminder that product cycles can slip, and the valuation should discount a non-trivial chance that the next catalyst disappoints or requires rework. Near term, the tape is about H2 readouts and whether Miebo/TRx momentum and premium mix stay intact; over 6-18 months, the real falsifier is a stall in dry-eye growth or a failure to keep leverage trending toward management’s target.

Key Decisions for Investors

• Initiate a tactical long BLCO on weakness after the print; thesis is underappreciated operating leverage, with a 3-6 month catalyst path from margin/deliverable cash flow and H2 pipeline updates.
• Add a pair trade: long BLCO / short ALC for 1-3 months to express premium IOL share capture and mix-upgrade upside without taking full ophthalmology beta.
• Keep BLCO as a monitored long only if Miebo growth stays above the current mid-40% range and premium IOL mix holds above low-teens; if either rolls over for two consecutive quarters, reduce/exit.
• Watch for an event-driven re-entry after the dual-action dry-eye readout and ELIOS regulatory progress; positive data could justify a rerating, while a delay is the main near-term downside catalyst.
• Do not chase with options until the enVista Beyond path is clarified; the stock is attractive, but the pipeline still carries genuine development risk and deserves a smaller initial size.